Controversial plans to dramatically reduce the rebate for intravitreal injections and also allow non-ophthalmologists to perform the procedure have divided Australia’s eyecare sector, with advocacy bodies considering the implications for patients. Read more
A new Australian study linking low vitamin D levels with uveitis has suggested investigating whether supplements could help prevent a relapse of the condition in at-risk patients.
Australian research comparing Carl Zeiss’ SITA-Standard and SITA-Faster algorithms has concluded the latter saves time and is just as accurate when testing glaucoma patients, despite producing a higher rate of false-positive results.
Should optometrists move down the path of population-based screening programs, or does a more judicious, targeted approach ensure the best level of eyecare? Read more
The Optometry Board of Australia (OBA) has ended its two-year freeze on registration fees and set a 2.5% increase to align with indexation. Read more
Australian researchers have developed a world-first eye scan technology that can identify changes in the retina and predict the likelihood of developing Alzheimer’s disease later in life. Read more
An international consortium involving Australian researchers has identified two genes that cause the rare ocular condition macular telangiectasia type 2 (MacTel 2). Read more
New cases of incorrectly dispensed atropine formulations have prompted calls for eyecare professionals to make annotations to scripts in order to prevent further misunderstandings among pharmacists. Read more
Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more
Controversial recommendations to dramatically drop the rebate for intravitreal injections and allow optometrists and nurses to perform the procedure are part of a long-awaited ophthalmic Medicare Benefits Schedule (MBS) review.